Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1331-1340 of 1,873) with videos related to

Pageof 188
Sort By:
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Acta Cytologica|February 28, 1998
ASCUS and AGUS criteria. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and TutorialD Solomon, W J Frable, G P Vooijs, et al.
European Journal of Heart Failure|May 1, 2020
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREPooja Dewan, Alice Jackson, Pardeep S Jhund, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Hypertension (Dallas, Tex. : 1979)|October 29, 2014
High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities studyYashashwi Pokharel, Wensheng Sun, James A de Lemos, et al.
European Journal of Heart Failure|July 29, 2020
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERESøren Lund Kristensen, Davide Castagno, Li Shen, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
Pageof 188

Showing results (1331-1340 of 1,873) with videos related to

Sort By:
Pageof 188
European Heart Journal|August 31, 2025
Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
Acta Cytologica|February 28, 1998
ASCUS and AGUS criteria. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and TutorialD Solomon, W J Frable, G P Vooijs, et al.
European Journal of Heart Failure|May 1, 2020
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREPooja Dewan, Alice Jackson, Pardeep S Jhund, et al.
Circulation|September 9, 2022
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic SubstudyAmil M Shah, Brian Claggett, Narayana Prasad, et al.
Hypertension (Dallas, Tex. : 1979)|October 29, 2014
High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities studyYashashwi Pokharel, Wensheng Sun, James A de Lemos, et al.
European Journal of Heart Failure|July 29, 2020
Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERESøren Lund Kristensen, Davide Castagno, Li Shen, et al.
Circulation|November 20, 2014
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fractionSøren L Kristensen, Lars Køber, Pardeep S Jhund, et al.
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
Pageof 188